ASX - By Stock
|
MSB |
Re:
Ann: Becoming a substantial holder
|
|
ant590
|
87 |
47K |
0 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
87
|
47K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
ant590
|
1.0K |
406K |
10 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
406K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
ant590
|
1.0K |
406K |
4 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
406K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
ant590
|
1.0K |
406K |
8 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
406K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
ant590
|
1.0K |
406K |
9 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
406K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
ant590
|
1.0K |
406K |
17 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
406K
|
17
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
ant590
|
80 |
24K |
0 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
80
|
24K
|
0
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Company Update
|
|
ant590
|
75 |
29K |
3 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
75
|
29K
|
3
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Company Update
|
|
ant590
|
75 |
29K |
4 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
75
|
29K
|
4
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
ant590
|
288 |
83K |
1 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
288
|
83K
|
1
|
|
ASX - By Stock
|
ADO |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
ant590
|
288 |
83K |
1 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
288
|
83K
|
1
|
|
ASX - By Stock
|
NSB |
Re:
Ann: Investor Update Webinar
|
|
ant590
|
51 |
15K |
3 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
51
|
15K
|
3
|
|
ASX - By Stock
|
NSB |
Re:
Ann: Investor Update Webinar
|
|
ant590
|
51 |
15K |
18 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
51
|
15K
|
18
|
|
ASX - By Stock
|
NSB |
Re:
Ann: Investor Update Webinar
|
|
ant590
|
51 |
15K |
6 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
51
|
15K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast 2021 Full Year Financial Results Webcast
|
|
ant590
|
195 |
65K |
8 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
195
|
65K
|
8
|
|
ASX - By Stock
|
ADO |
Re:
Ann: AnteoTech Signs SE Asian Distribution Agreement for EuGeni
|
|
ant590
|
320 |
108K |
7 |
19/07/21 |
19/07/21 |
ASX - By Stock
|
320
|
108K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
AGM Discussion
|
|
ant590
|
254 |
100K |
12 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
254
|
100K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
ant590
|
576 |
235K |
6 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
576
|
235K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
ant590
|
392 |
160K |
43 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
392
|
160K
|
43
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel Controlled Study in Crohns & Ulcerative Colitis
|
|
ant590
|
102 |
53K |
4 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
102
|
53K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
ant590
|
13K |
5.0M |
4 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
13K
|
5.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
ant590
|
576 |
235K |
5 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
576
|
235K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
10 Sept 12pm NSW Stem Cell Network - Stem Cells vs COVID19
|
|
ant590
|
220 |
85K |
10 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
220
|
85K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
NIH dismisses FDA EUA of plasma
|
|
ant590
|
22 |
8.5K |
11 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
22
|
8.5K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
NIH dismisses FDA EUA of plasma
|
|
ant590
|
22 |
8.5K |
19 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
22
|
8.5K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
ant590
|
576 |
235K |
116 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
576
|
235K
|
116
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
ant590
|
576 |
235K |
3 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
576
|
235K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Conference call details here
|
|
ant590
|
38 |
12K |
11 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
38
|
12K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Conference call details here
|
|
ant590
|
38 |
12K |
2 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
38
|
12K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
3 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
$5 party?
|
|
ant590
|
108 |
41K |
12 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
108
|
41K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
10 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
11 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
27 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
2 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
16 |
14/08/20 |
14/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
7 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
1 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ryoncil: ODAC/FDA Meeting Discussion
|
|
ant590
|
2.0K |
698K |
4 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
2.0K
|
698K
|
4
|
|
ASX - By Stock
|
BUB |
Re:
Ann: Bubs Australia Launches Vita Bubs Range in Chemist Warehouse
|
|
ant590
|
18 |
9.1K |
0 |
27/07/20 |
27/07/20 |
ASX - By Stock
|
18
|
9.1K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Analyst Call - Part Two
|
|
ant590
|
26 |
11K |
9 |
29/05/20 |
29/05/20 |
ASX - By Stock
|
26
|
11K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
|
|
ant590
|
127 |
71K |
3 |
25/05/20 |
25/05/20 |
ASX - By Stock
|
127
|
71K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 3 Articles on RYONCIL GvHD Trial Results Published in BBMT
|
|
ant590
|
127 |
71K |
8 |
25/05/20 |
25/05/20 |
ASX - By Stock
|
127
|
71K
|
8
|
|